Desensitization for renal transplantation: depletion of donor‐specific anti‐HLA antibodies, preservation of memory antibodies, and clinical risks

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Transplant International

• Publication date

  2011-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1432-2277.2010.01138.xPMID 20698938
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Appendix II

  2020cited by this paper
• Incidence and Predictive Factors for Infectious Disease after Rituximab Therapy in Kidney‐Transplant Patients

  2010cited by this paper
• Immunogenetics and immunology in transplantation

  2010cited by this paper
• Use of Intravenous Immune Globulin and Rituximab for Desensitization of Highly HLA-Sensitized Patients Awaiting Kidney Transplantation

  2010cited by this paper
• Deciphering antibody-mediated rejection: new insights into mechanisms and treatment

  2010cited by this paper
• Proinflammatory Events Are Associated with Significant Increases in Breadth and Strength of HLA‐Specific Antibody

  2009cited by this paper
• Clinical significance of anti-HLA antibodies detected by Luminex: enhancing the interpretation of CDC-BXM and important post-transplantation monitoring tools.

  2009cited by this paper
• MODULATION OF ISCHEMIA REPERFUSION INJURY BY THE NANOPARTICLE DELIVERY OF C3 SPECIFIC SMALL INTERFERING RNA (SIRNA): 314

  2008cited by this paper
• Anti‐HLA Donor‐Specific Antibodies Detected in Positive B‐Cell Crossmatches by Luminex® Predict Late Graft Loss

  2008cited by this paper
• Maintenance of Long-Lived Plasma Cells and Serological Memory Despite Mature and Memory B Cell Depletion during CD20 Immunotherapy in Mice1

  2008cited by this paper
• Detecting and monitoring human leukocyte antigen-specific antibodies.

  2008cited by this paper
• “Natural” Human Leukocyte Antigen Antibodies Found in Nonalloimmunized Healthy Males

  2008cited by this paper
• Infectious complications associated with the use of rituximab for ABO‐incompatible and positive cross‐match renal transplant recipients

  2007cited by this paper
• Interferon-alpha therapy and anti-human leukocyte antigen antibodies in hepatitis C virus-positive patient: case report.

  2007cited by this paper
• Interferon-α Therapy and Anti–Human Leukocyte Antigen Antibodies in Hepatitis C Virus–Positive Patient: Case Report

  2007cited by this paper
• Anti-HLA antibody repertoire after IVIg infusion in highly sensitized patients waiting for kidney transplantation.

  2006cited by this paper
• A Comparison of Plasmapheresis Versus High‐Dose IVIG Desensitization in Renal Allograft Recipients with High Levels of Donor Specific Alloantibody

  2006cited by this paper
• Peritransplant Immunoadsorption: A Strategy Enabling Transplantation in Highly Sensitized Crossmatch-Positive Cadaveric Kidney Allograft Recipients

  2005cited by this paper
• Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy1

  2005cited by this paper
• Highly successful living donor kidney transplantation after conversion to negative of a previously positive flow-cytometry cross-match by pretransplant plasmapheresis.

  2005cited by this paper
• Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics1

  2004cited by this paper
• Persistence of Low Levels of Alloantibody after Desensitization in Crossmatch-Positive Living-Donor Kidney Transplantation

  2004cited by this paper
• In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody

  2004influential reference
• Circulating anti-HLA antibodies in patients with chronic hepatitis C: relation to disease activity.

  2004cited by this paper
• Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.

  2004cited by this paper
• Overcoming a Positive Crossmatch in Living‐Donor Kidney Transplantation

  2003cited by this paper
• Anti-human leukocyte antigen (HLA) antibodies in non-transfused, non-transplanted patients with chronic hepatitis C

  2003cited by this paper
• Desensitization and Subsequent Kidney Transplantation of Patients Using Intravenous Immunoglobulins (IVIg)

  2002cited by this paper
• B-Cell crossmatching and kidney allograft outcome in 9031 United States transplant recipients.

  2002cited by this paper
• Transplant Accommodation in Highly Sensitized Patients: A Potential Role for Bcl‐xL and Alloantibody

  2001cited by this paper
• A HIGH PANEL-REACTIVE ANTIBODY RESCUE PROTOCOL FOR CROSS-MATCH-POSITIVE LIVE DONOR KIDNEY TRANSPLANTS1

  2000cited by this paper
• Effect of waiting time on renal transplant outcome.

  2000cited by this paper
• Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.

  1999cited by this paper
• Impaired renal graft survival after a positive B-cell flow-cytometry crossmatch.

  1998cited by this paper
• IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

  1997cited by this paper
• Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation.

  1996cited by this paper
• Report of renal failure treatment in Australia and New Zealand from the dialysis and transplant registry (ANZDATA)

  1995cited by this paper
• Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation.

  1989cited by this paper
• Significance of the positive crossmatch test in kidney transplantation.

  1969cited by this paper

• Recommendations for living donor kidney transplantation.

  2022cites this paper
• Low Incidence of Acute Antibody-Mediated Rejection after HLA Desensitization in Living Donor Kidney Transplant Recipients

  2022cites this paper
• Recomendaciones para el trasplante renal de donante vivo

  2022cites this paper
• Living Donor Kidney Transplantation in Patients With Donor-Specific HLA Antibodies After Desensitization With Immunoadsorption

  2018cites this paper
• Renal Transplantation Across HLA and ABO Barriers

  2017cites this paper
• Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation.

  2015cites this paper
• Antibody-Mediated Rejection: Analyzing the Risk, Proposing Solutions

  2014cites this paper
• Belatacept for kidney transplant recipients.

  2014cites this paper
• Desensitization in kidney transplantation: review and future perspectives

  2014cites this paper
• Effects of mycophenolic acid on highly sensitized patients awaiting kidney transplant.

  2013cites this paper
• Analysis of Anti-HLA Antibodies in Sensitized Kidney Transplant Candidates Subjected to Desensitization with Intravenous Immunoglobulin and Rituximab

  2013cites this paper
• Detection of Antibody-Mediated Rejection in Kidney Transplantation and the Management of Highly Sensitised Kidney Transplant Recipients

  2013cites this paper
• Living donor kidney transplantation in crossmatch‐positive patients enabled by peritransplant immunoadsorption and anti‐CD20 therapy

  2012cites this paper
• Transplant glomerulopathy and rapid allograft loss in the presence of HLA‐Cw7 antibodies

  2012cites this paper
• Characteristics, Detection, and Clinical Relevance of Alloantibodies in Kidney Transplantation

  2011cites this paper
• Histocompatibility testing after fifty years of transplantation.

  2011cites this paper
• PRIPREMA VISOKO HLA-SENZIBILIZIRANE BOLESNICE ZA TRANSPLANTACIJU SRCA: PRVI SLUČAJ U REPUBLICI HRVATSKOJ

  2011cites this paper
• Rituximab and memory antibody levels after desensitization

  2011cites this paper